Search / Trial NCT00001408

Role of T-Cells in Asthma

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Nov 3, 1999

Trial Information

Current as of December 26, 2024

Completed

Keywords

Lymphocytes Asthma Cytokines Interleukin 5 Late Phase Response

ClinConnect Summary

In the last 10 years it has become generally accepted that asthma is an inflammatory disease of the airways. T lymphocytes play a key role in regulating this inflammatory response, through the elaboration of cytokines such as IL-4, IL-5, and IFN-gamma. IL-5 is of particular interest because it is the major eosinophil survival factor in vivo. Eosinophils are felt to be the major effector cells in asthma, causing damage to various airway structures.

The pulmonary late phase response, a worsening of airflow seen 4-8 hours after allergen inhalation, is associated with many of the inflammatory ...

Gender

ALL

Eligibility criteria

  • * INCLUSION CRITERIA - BLOOD DRAW/ASTHMA:
  • Age 18-65.
  • Asthma of greater than one year duration.
  • Willingness to adhere to effective contraception in women of child bearing age.
  • Negative HIV test.
  • EXCLUSION CRITERIA - BLOOD DRAW/ASTHMA:
  • For blood draws of greater than 100 ml, a hemoglobin of less than 12.5 g/dl. For blood draws of 100 ml or less, performed less frequently than every 56 days, a hemoglobin of less than 10.0 g/dl.
  • Current pregnancy.
  • Medical history suggesting lung diseases other than asthma.
  • History of immunodeficiency or HIV infection.
  • INCLUSION CRITERIA - BLOOD DRAW/NORMAL CONTROL:
  • Age 18-65.
  • Willingness to adhere to effective contraception in women of child bearing age.
  • Negative HIV test.
  • EXCLUSION CRITERIA - BLOOD DRAW/NORMAL CONTROL:
  • For blood draws of greater than 100 ml, a hemoglobin of less than 12.5 g/dl. For blood draws of 100 ml or less, performed less frequently than every 56 days, a hemoglobin of less than 10.0 g/dl.
  • Current pregnancy.
  • Positive skin test to one or more allergens in the battery tested.
  • History of asthma or other allergic diseases, such as hay fever.
  • Medical history suggesting lung diseases other than asthma.
  • History of immunodeficiency or HIV infection.
  • INCLUSION CRITERIA - EXHALED BREATH CONDENSATE/ASTHMA:
  • Age 18-65.
  • Asthma as diagnosed by a physician or use of medications consistent with the treatment of asthma.
  • Subjects must have a doctor outside NIH and they will provide routine and emergency care.
  • EXCLUSION CRITERIA - EXHALED BREATH CONDENSATE/ASTHMA:
  • History of immunodeficiency or HIV infection.
  • History of allergy to latex.
  • INCLUSION CRITERIA - EXHALED BREATH CONDENSATE/HEALTHY CONTROL:
  • Age 18 - 65.
  • EXCLUSION CRITERIA - EXHALED BREATH CONDENSATE/HEALTHY CONTROL:
  • History of asthma or other allergic diseases, such as allergic rhinitis.
  • Medical history suggesting lung diseases other than asthma.
  • History of allergy to latex.
  • History of immunodeficiency or HIV infection.

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials